



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION

Clone ID	1H6
Target	CL2A
Synonyms	N.A.
Host Species	Rabbit
Description	PE-conjugated Anti-CL2A(ADC linker) antibody(1H6); Rabbit mAb
Delivery	Under Development
Uniprot ID	N.A.
IgG type	Rabbit IgG
Clonality	Monoclonal
Reactivity	N.A.
Applications	Flow Cyt
Recommended Dilutions	Flow Cyt 1:100
Purification	Purified from cell culture supernatant by affinity chromatography
Formulation & Reconstitution	Liquid□PBS with 0.05% Proclin300, 1% BSA
Storage & Shipping	Store at 2°C-8°C for 6 months
Background	CL2A is a crucial component in antibody-drug conjugate (ADC) therapy, acting as a chemical linker that connects a potent DNA topoisomerase I inhibitor, SN-38, to an antibody. Representing Cysteine-Linked 2-Aminoethyl, CL2A features a complex structure with a PEG8 chain, a triazole ring, a PABC-peptide, and a maleimide group. The maleimide group binds to a cysteine residue on the antibody, facilitating targeted drug delivery. Designed to release SN-38 in acidic cancer cell environments, CL2A induces DNA damage and cell death. This versatile linker is employed in ADCs targeting various antigens like Trop-2 or HER2, tailored to specific cancer types.
Usage	Research use only
Conjugate	PE-conjugated
DIMA Disclaimer	All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.

